DE19704301C1 - Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie - Google Patents

Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Info

Publication number
DE19704301C1
DE19704301C1 DE19704301A DE19704301A DE19704301C1 DE 19704301 C1 DE19704301 C1 DE 19704301C1 DE 19704301 A DE19704301 A DE 19704301A DE 19704301 A DE19704301 A DE 19704301A DE 19704301 C1 DE19704301 C1 DE 19704301C1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid construct
promoter
gene
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19704301A
Other languages
German (de)
English (en)
Inventor
Wolff Graulich
Dirk Nettelbeck
Hans Harald Sedlacek
Rolf Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE19704301A priority Critical patent/DE19704301C1/de
Priority to MXPA/A/1998/000981A priority patent/MXPA98000981A/xx
Priority to ARP980100497A priority patent/AR011110A1/es
Priority to TR1998/00168A priority patent/TR199800168A2/xx
Priority to CA002222981A priority patent/CA2222981A1/en
Priority to CZ1998332A priority patent/CZ289227B6/cs
Priority to HU9800247A priority patent/HUP9800247A3/hu
Priority to JP10024524A priority patent/JPH11178A/ja
Priority to KR1019980003185A priority patent/KR19980071084A/ko
Priority to RU98101849/13A priority patent/RU2230115C2/ru
Priority to EP98102014A priority patent/EP0857781A3/de
Priority to AU52931/98A priority patent/AU736724B2/en
Priority to CNB981063500A priority patent/CN1196784C/zh
Priority to BR9800563A priority patent/BR9800563A/pt
Priority to PL98324688A priority patent/PL324688A1/xx
Priority to US09/019,689 priority patent/US6103527A/en
Application granted granted Critical
Publication of DE19704301C1 publication Critical patent/DE19704301C1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
DE19704301A 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie Expired - Fee Related DE19704301C1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE19704301A DE19704301C1 (de) 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
ARP980100497A AR011110A1 (es) 1997-02-06 1998-02-04 Promotor del gen de endoglina humana, una construccion de acido nucleico que comprende al menos una secuencia promotora del gen de endoglina humana, unacelula que alberga dicha construccion de acido nucleico, y el uso de dicha construccion de acido nucleico para preparar un farmaco
TR1998/00168A TR199800168A2 (xx) 1997-02-06 1998-02-04 �nsan endoglin geni y�kselticisi ve kullan�m�.
CA002222981A CA2222981A1 (en) 1997-02-06 1998-02-04 Promoter of the human endoglin gene and its use
CZ1998332A CZ289227B6 (cs) 1997-02-06 1998-02-04 Promotor lidského endoglinového genu a jeho pouľití pro přípravu léčiva
MXPA/A/1998/000981A MXPA98000981A (en) 1997-02-06 1998-02-04 Promoter of human endoglin gene and his
BR9800563A BR9800563A (pt) 1997-02-06 1998-02-05 Promotor de gene endoglina de ser humano e seu uso
KR1019980003185A KR19980071084A (ko) 1997-02-06 1998-02-05 사람 엔도글린 유전자의 프로모터 및 이의 용도
HU9800247A HUP9800247A3 (en) 1997-02-06 1998-02-05 Promoter for human endoglingene and its use
EP98102014A EP0857781A3 (de) 1997-02-06 1998-02-05 Promotor des humanen Endoglingens sowie seine Verwendung
AU52931/98A AU736724B2 (en) 1997-02-06 1998-02-05 Promoter of the human endoglin gene and its use
CNB981063500A CN1196784C (zh) 1997-02-06 1998-02-05 人内皮特异受体基因的启动子及其用途
JP10024524A JPH11178A (ja) 1997-02-06 1998-02-05 ヒトエンドグリン遺伝子プロモーターおよびその使用
RU98101849/13A RU2230115C2 (ru) 1997-02-06 1998-02-05 Промотор гена человеческого эндоглина и его применение
PL98324688A PL324688A1 (en) 1997-02-06 1998-02-06 Human endoglin gene promotor, nucleic acid construct, cell containing such construct, application of such construct in production of a pharmaceutic agent, method of obtaining such pharmaceutic agent and pharmaceutic agent obtained thereby
US09/019,689 US6103527A (en) 1997-02-06 1998-02-06 Promoter of the human endoglin gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19704301A DE19704301C1 (de) 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Publications (1)

Publication Number Publication Date
DE19704301C1 true DE19704301C1 (de) 1998-03-26

Family

ID=7819364

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19704301A Expired - Fee Related DE19704301C1 (de) 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Country Status (15)

Country Link
US (1) US6103527A (enExample)
EP (1) EP0857781A3 (enExample)
JP (1) JPH11178A (enExample)
KR (1) KR19980071084A (enExample)
CN (1) CN1196784C (enExample)
AR (1) AR011110A1 (enExample)
AU (1) AU736724B2 (enExample)
BR (1) BR9800563A (enExample)
CA (1) CA2222981A1 (enExample)
CZ (1) CZ289227B6 (enExample)
DE (1) DE19704301C1 (enExample)
HU (1) HUP9800247A3 (enExample)
PL (1) PL324688A1 (enExample)
RU (1) RU2230115C2 (enExample)
TR (1) TR199800168A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036926A2 (de) 1998-04-09 2009-03-18 Affitech AS Einzelkettiges, mehrfach-antigenbindendes Molekül, dessen Herstellung und Verwendung

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
DE60013586T2 (de) 1999-04-02 2005-02-03 Hisamitsu Pharmaceutical Co., Inc., Tosu Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
RU2295281C2 (ru) * 2005-04-20 2007-03-20 Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург Способ оценки тяжести инфекционного поражения цнс у детей
RU2297848C2 (ru) * 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
WO2014123749A1 (en) 2013-01-30 2014-08-14 Board Of Regents Of The University Of Nebraska Compositions and methods for treating complications associated with diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466596A (en) * 1992-08-25 1995-11-14 Mount Sinai Hospital Corporation Tissue specific transcriptional regulatory element
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gene 138, S.201 u. 206, 1994 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036926A2 (de) 1998-04-09 2009-03-18 Affitech AS Einzelkettiges, mehrfach-antigenbindendes Molekül, dessen Herstellung und Verwendung
US7838637B2 (en) 1998-04-09 2010-11-23 Affitech Research As Single-chain multiple antigen-binding molecule, its preparation and use

Also Published As

Publication number Publication date
AU736724B2 (en) 2001-08-02
BR9800563A (pt) 1999-06-29
CN1196784C (zh) 2005-04-13
HUP9800247A2 (hu) 1998-10-28
CA2222981A1 (en) 1998-08-06
RU2230115C2 (ru) 2004-06-10
EP0857781A3 (de) 2001-05-16
CZ289227B6 (cs) 2001-12-12
HUP9800247A3 (en) 2002-11-28
CN1203948A (zh) 1999-01-06
JPH11178A (ja) 1999-01-06
MX9800981A (es) 1998-08-30
CZ33298A3 (cs) 1998-08-12
HU9800247D0 (en) 1998-03-30
AR011110A1 (es) 2000-08-02
PL324688A1 (en) 1998-08-17
KR19980071084A (ko) 1998-10-26
EP0857781A2 (de) 1998-08-12
TR199800168A2 (xx) 1998-08-21
AU5293198A (en) 1998-08-13
US6103527A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
EP0777740B1 (de) Gentherapeutische behandlung von erkrankungen des zentralen nervensystems (zns) durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DE69533264T2 (de) Inhibitoren der il-6 aktivitaet
DE69733605T2 (de) In vivo gentransfermethoden zur wundheilung
DE69431736T2 (de) Neues Chemokine von hematopoietischen Zellen produziert und die dafür kodierende DNA
DE69936538T2 (de) Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert
DE69634412T2 (de) Regulierte gene und ihre verwendungen
DE19704301C1 (de) Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
DE69732847T2 (de) Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
DE69921609T2 (de) Ribozymale nukleinsäure die ccr5 oder cxcr4 schneiden
DE19710643A1 (de) Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie
DE19617851A1 (de) Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
EP2978402B1 (de) Stabilisiertes polyribonucleotid codierend für ein elastisches faserprotein
EP0299303B1 (de) Eukaryotische Expressionsvektoren mit multimeren Enhancer-Subelementen, Verfahren zu ihrer Herstellung und Verwendung
DE60208066T2 (de) Promotoren zur kontrolle der zelldifferenzierung
EP0980251B1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69229613T2 (de) Neurotrophen-Peptidderivat
WO2002068669A2 (de) Episomale vektoren enthaltend matrix-anheftungsregionen zur zellspezifischen genexpression
DE19545351C1 (de) Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie
DE3854195T2 (de) Polypeptid-verbindungen.
JP2022501050A (ja) 細胞のテロメアを伸長させる方法
DE68915375T2 (de) Gen-Expression regulierender Faktor.
DE69331730T2 (de) Aus nerven gewonnenes transglutaminase-enzym für die induktion der nervenregeneration
DE60117641T2 (de) Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide
HK1017713A (en) Promoter of the human endoglin gene and its use
DE3724482C2 (de) Verfahren zur Erweiterung der Zellspezifität von eukaryotischen Expressionsvektoren

Legal Events

Date Code Title Description
8100 Publication of patent without earlier publication of application
D1 Grant (no unexamined application published) patent law 81
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, 65929 FRANKFURT,

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8339 Ceased/non-payment of the annual fee